Domain Therapeutics, a French and Canadian privately-held biopharmaceutical company, is using transmembrane and G Protein-Coupled Receptor (GPCR) targeting for the discovery and development of innovative therapeutics for the treatment of Central Nervous System (CNS) diseases and cancer.
Using its commercially proven candidate discovery engine (Takeda, Merck Serono and ONO Pharmaceutical), Domain has created a pipeline of high-value projects and partnerships. Validating this approach, two projects discovered by Domain Therapeutics technologies are planned to enter clinical Phase I in early and late 2016.
Domain Therapeutics applies a multi-string corporate strategy to grow its business through:
Domain Therapeutics appoints Xavier Leroy as chief technology officer190708-domain-cto-eng.pdf
Domain Therapeutics strengthens its scientific advisory board with leading GPCR and disease experts
Domain Therapeutics appoints Sylvie Ryckebusch to board of directors
European Venture Capital Firm Seventure Partners renews its support to Domain Therapeutics and invests €3.5M ($3.9M) to prepare the next growth phase